Association between C13ORF31, NOD2, RIPK2 and TLR10 polymorphisms and urothelial bladder cancer
Metadatos
Mostrar el registro completo del ítemAutor
Guirado, Macarena; Gil, Hernani; Sáenz-López, Pablo; Reinboth, Jennifer; Garrido Torres-Puchol, Federico; Cózar Olmo, José Manuel; Ruiz-Cabello Osuna, Francisco; Carretero Coca, RafaelEditorial
Elsevier
Materia
C13ORF31 NOD2 RIPK2 TLR10 Cancer Prognosis Polymorphism bladder
Fecha
2012-06Referencia bibliográfica
Hum Immunol. 2012 Jun;73(6):668-72. doi: 10.1016/j.humimm.2012.03.006. Epub 2012 Apr 12.
Patrocinador
Departamento de Bioquímica III e Inmunología, Universidad de Granada, Spain; Servicio de Urología, Hospital Universitario Virgen de las Nieves, Granada, Spain; Servicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, Granada, Spain; Genelux Corporation, San Diego Science Center, San Diego, CA, USAResumen
Several evidences have been published linking polymorphism in genes involved in chronic or recurrent inflammation with increased tumor risk and progression. Nevertheless the influence of innate immune receptors in urothelial cancer risk and characteristics has not been sufficient explored. We studied the possible association of polymorphisms in genes encoding NOD2, RIPK2, TLR10 and C13ORF31 with the risk, clinical/pathological characteristics and outcomes of urothelial cancer. We have found association between RIPK2 (rs42490) and cancer risk (AA vs AT&TT, p=0042). In addition, we found statistical differences in TLR10 (rs4129009) gen between low and high tumor infiltration stage (p=0.033). NOD2 (rs9302752) and RIPK2 (rs42490) were found to be associated with development of lymph node metastasis (p=0.011 and p=0.015). Importantly we detect association of TLR10 (Log Rank=0.035) and RIPK2 (Log Rank=0040) with overall survival. Multivariate Cox analysis revealed that both SNPs were survival prognosis factor independent of tumor stage and grade. Our results indicate that innate immunity receptors play a role in modulating urothelial cancer risk and progression.





